Iloperidone (Fanapt) vs Paliperidone palmitate (Invega Trinza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Paliperidone palmitate (Invega Trinza)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Weak signal

NCT02713282 · Phase 3 · completed

This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Paliperidone palmitate (Invega Trinza)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342
CGI-S, change—Trial running · NCT069619680 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results
PANSS response—Trial running · NCT06961968—Not posted · NCT02713282
PSP, change—Trial running · NCT069619681 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
Relapse (% of patients)—Trial running · NCT06961968—Not posted · NCT02713282

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Paliperidone palmitate (Invega Trinza)
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Trinza)
0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Trinza)
1 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Iloperidone (Fanapt): 5 of 5 rows · Paliperidone palmitate (Invega Trinza): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Paliperidone palmitate (Invega Trinza)
Time to Relapse
time to event · months
NA vs 3.25 placebo months @ 26wka,b,c
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
NA vs NA PP3M months @ 52wka,b,c
NCT03345342 · Phase 3 · Schizophrenia · phase 3
Dropout rate
34.6%d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
13.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
3.9%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Serious AEs
0.7%d
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
5%Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
4.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
2.5%
NCT01529515 · Phase 3
12.8%Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
d
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
e
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
700 or 1000 mg eq
headache 13.5%
blood prolactin increased 10.7%
hyperprolactinaemia 7.3%
NCT04072575 · Phase 3 · combination
headache 8.8% (placebo 4.1%)
weight increased 8.8% (placebo 3.4%)
anxiety 8.1% (placebo 10.3%)
NCT01529515 · Phase 3
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3 · registry result, not featured evidence
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation context differs: baseline_threshold differs (panss<=100 versus bmi>=17, panss<70); prior_therapy differs (experienced versus none recorded).
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 26 weeks versus 52 weeks.
  4. dPopulation comparability has not been reviewed for 21 of these studies.
  5. ePopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Paliperidone palmitate (Invega Trinza)

CGI-S 0 vs 0 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
-0.2 vs -0.3 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs -0.7 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence
PSP 1 vs 1.1 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3 · registry result, not featured evidence
Symptomatic Remission 66.3% (n=478) vs 70.1% (n=224) PP3M @ 52wk
responder rate · % of participants
NCT03345342 · Phase 3 · Schizophrenia · phase 3
Relapse 3.9% (n=178) @ 104wk700 or 1000 mg eq
event count · % of participants
No placebo or comparator arm
NCT04072575 · Phase 3 · combination · converted to % from 7 Participants as posted
CGI-S 0 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PSP 0.5 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PANSS Total 0.7 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
Time to Relapse Median NA vs 12.98 placebo months @ 60wk
time to event · months
NCT01529515 · Phase 3
PANSS Total -0.5 vs 6.7 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
CGI-S 0.1 vs 0.4 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
PSP -0.5 vs -4.2 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Paliperidone palmitate (Invega Trinza)'s landscape